Studies Have Shown That Haart May Be Able To Treat Covid-19, With Some Patients Recovering Faster After Use

Some scientists say patients with mild to moderate covid-19 who receive a three-drug cocktail may get better faster than those who receive only a two-drug combination.


According to the New York times, researchers are rushing to determine whether existing drugs can be used to treat covid-19. In the United States, only redesivir has been shown to be effective in speeding recovery. In The new study, published in The Lancet, researchers at six public hospitals in Hong Kong and The university of Hong Kong followed 127 adult patients with covid-19, 86 of whom took a combination of three drugs and 41 of whom took a control drug.

The study showed that patients who took all three drugs seemed to recover more quickly and had a much shorter hospital stay than the control group. The cocktail includes three antiviral drugs: lopinavir – ritonavir, taken orally; Ribavirin, an antiviral drug used to treat hepatitis c, is also taken orally; Interferon -1b, an injectable drug used to treat multiple sclerosis, regulates inflammation and inhibits viral growth. Some experts believe that interferon may enhance the body’s ability to fight novel coronavirus.

Participants in the control group received only lopinavir – ritonavir. Patients taking three drugs tested negative for novel coronavirus within an average of seven days, while those taking one drug tested negative within an average of 12 days. Haart also halved the duration of covid-19 symptoms, from eight days to four.


“This is good news,” said Dr. Sarah Shalhoub, an infectious disease expert at the University of Western University in Ontario, Canada. “it suggests that patients can recover faster and require less time in the hospital.” But she cautioned that all the subjects in the study were mild to moderate patients, and that whether the combination of drugs would benefit critically ill patients was an important question. “Whether these results will be replicated in patients who need a lot of oxygen and end up in intensive care is another matter,” Dr. Shalhob said.